Stanton Gerson
22Patents
7h-index
24Co-inventors
69Inventor score
Filing activity: Dec 4, 1991 → Dec 26, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5591625A | Transduced mesenchymal stem cells | Chemistry; Metallurgy | 234 | Expired |
| US6010696A | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells | Chemistry; Metallurgy | 129 | Expired |
| US5733542A | Enhancing bone marrow engraftment using MSCS | Chemistry; Metallurgy | 124 | Expired |
| US6465448B1 | Methoxyamine potentiation of temozolomide anti-cancer activity | Human Necessities | 21 | Expired |
| US8324282B2 | Alkylating agent combinations in the treatment of cancer | Human Necessities | 14 | Expired |
| US9789116B2 | Compositions and methods of modulating short-chain dehydrogenase activity | Chemistry; Metallurgy | 7 | Active |
| US9801863B2 | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis | Human Necessities | 7 | Active |
| US9790233B2 | Compositions and methods of modulating 15-PGDH activity | Chemistry; Metallurgy | 7 | Active |
| US5300422A | Screening method for controlling agranulocytosis | Emerging Cross-Sectional Technologies | 7 | Expired |
| US10301320B2 | Compositions and methods of modulating 15-PGDH activity | Chemistry; Metallurgy | 6 | Active |
| US10869871B2 | Compositions and methods of modulating short-chain dehydrogenase activity | Chemistry; Metallurgy | 5 | Active |
| US6635677B2 | Methoxyamine combinations in the treatment of cancer | Human Necessities | 5 | Expired |
| US10945998B2 | Inhibitors of short-chain dehydrogenase activity for treating fibrosis | Emerging Cross-Sectional Technologies | 3 | Active |
| US5965126A | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents | Human Necessities | 2 | Expired |
| US8716346B2 | Alkylating agent combinations in the treatment of cancer | Human Necessities | 1 | Active |
| US10718028B2 | Fluorescent probes for abasic site detection | Chemistry; Metallurgy | 0 | Active |
| US8791081B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | Human Necessities | 0 | Active |
| US9498489B2 | Antimetabolite agent combinations in the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US8318495B1 | Hematopoietic progenitor cell gene transduction | Chemistry; Metallurgy | 0 | Expired |
| US8367332B2 | Detection and quantification of abasic site formation in vivo | Physics | 0 | Active |
| US10722530B2 | Methods of diagnosing and treating cancer | Human Necessities | 0 | Active |
| US10725042B2 | Methods of diagnosing and treating cancer | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.